OBJECTIVE: To investigate the expression of @entity1364 (Ki-67) in stage III cervical @entity957 ( @entity957 ) and its correlation with the effect of chemotherapy on sensitivity to radiotherapy. METHODS: In 50 @entity1 with stage III cervical @entity957 ( @entity957 ), 25 @entity1 were treated with radiotherapy and 25 @entity1 were treated with chemoradiotherapy. The expression of Ki-67 in the biopsy specimens of cervical @entity957 was detected by immunohistochemistry at diagnosis and after 10 Gy radiotherapy. The correlation of Ki-67 positive cells percentage and chemotherapy with sensitivity to radiotherapy was analyzed. RESULTS: In 25 @entity1 with more than 48% Ki-67 positive cells at diagnosis, the rate of complete response (CR) was 72.0% (18/25). In 25 @entity1 with less than 48% Ki-67 positive cells at diagnosis, the CR rate was 40.0% (10/25), with a significant difference between them (P = 0.023). In 26 @entity1 with more than 31% decrease of Ki-67 positive cells after 10 Gy radiotherapy, the CR rate was 84.6% (22/26). In 24 @entity1 with less than 31% decrease of Ki-67 positive cells after 10 Gy radiotherapy, the CR rate was 25.0% (6/24), showing a significant difference between the two groups (P < 0.001). In the cases of Ki-67<48%, decrease of Ki-67 positive cells of chemoradiotherapy group after 10 Gy radiotherapy was significantly higher than that of the radiotherapy group (P = 0.023). In the cases of Ki-67 >=  48%, no difference in the decease of Ki-67 positive cells between the chemoradiotherapy and radiotherapy groups was found (P = 0.173). For the radiotherapy-sensitive @entity1 with CR recently, the 2-year progression free survival (PFS) rate and overall survival (OS) rate were 85.7% and 92.9%, respectively, both were significantly higher than those of radiotherapy-insensitive @entity1 (18.2% and 40.9%, P < 0.05 for both). CONCLUSIONS: In stage III cervical @entity957 , the expression of Ki-67 before and after treatment with 10 Gy radiotherapy may be used as a biomarker to predict @entity5 response to radiation, and guide the choice of therapeutic strategies. Yet, the effect of chemotherapy as a radiosensitizer is unconspicuous.

[Ki-67 expression in stage III cervical XXXX and its correlation with sensitivity to chemoradiotherapy].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'SCC'] @entity1364 :: ('5111', 'Gene') :: ['proliferating cell nuclear antigen'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity957 :: (MESH:D002294,Disease) :: ['squamous cell carcinoma']
